The online version of this article (doi:10.1186/s13054-017-1916-6) contains supplementary material, which is available to authorized users.
An optimal therapy for the treatment of pneumonia caused by drug-resistant Acinetobacter baumannii remains unclear. This study aims to compare various antimicrobial strategies and to determine the most effective therapy for pneumonia using a network meta-analysis.
Systematic search and quality assessment were performed to select eligible studies reporting one of the following outcomes: all-cause mortality, clinical cure, and microbiological eradication. The primary outcome was all-cause mortality. A network meta-analysis was conducted with a Bayesian approach. Antimicrobial treatments were ranked based on surface under the cumulative ranking curve (SUCRA) value along with estimated median outcome rate and corresponding 95% credible intervals (CrIs). Two treatments were considered significantly different if a posterior probability of superiority (P) was greater than 97.5%.
Twenty-three studies evaluating 15 antimicrobial treatments were included. Intravenous colistin monotherapy (IV COL) was selected as a common comparator, serving as a bridge for developing the network. Five treatments ranked higher than IV COL (SUCRA, 57.1%; median all-cause mortality 0.45, 95% CrI 0.41–0.48) for reducing all-cause mortality: sulbactam monotherapy (SUL, 100.0%; 0.18, 0.04–0.42), high-dose SUL (HD SUL, 85.7%; 0.31, 0.07–0.71), fosfomycin plus IV COL (FOS + IV COL, 78.6%; 0.34, 0.19–0.54), inhaled COL plus IV COL (IH COL + IV COL, 71.4%; 0.39, 0.32–0.46), and high-dose tigecycline (HD TIG, 71.4%; 0.39, 0.16–0.67). Those five treatments also ranked higher than IV COL (SUCRA, 45.5%) for improving clinical cure (72.7%, 72.7%, 63.6%, 81.8%, and 90.9%, respectively). Among the five treatments, SUL (P = 98.1%) and IH COL + IV COL (P = 99.9%) were significantly superior to IV COL for patient survival and clinical cure, respectively. In terms of microbiological eradication, FOS + IV COL (P = 99.8%) and SUL (P = 98.9%) were significantly superior to IV COL.
This Bayesian network meta-analysis demonstrated the comparative effectiveness of fifteen antimicrobial treatments for drug-resistant A. baumannii pneumonia in critically ill patients. For survival benefit, SUL appears to be the best treatment followed by HD SUL, FOS + IV COL, IH COL + IV COL, HD TIG, and IV COL therapy, in numerical order.
Additional file 1: Table S1. PRISMA checklist of items to include when reporting a systematic review and a network meta-analysis. (DOCX 20 kb)
Additional file 2: Table S2. Risk of bias assessment of randomized controlled trials. Table S3. Risk of bias assessment of observational studies. (DOCX 20 kb)
Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17:157–73. CrossRefPubMed
Ahn J, Choi SM, Cho S, Tchoe HJ. Bayesian meta-analysis method (English version). 1st ed. Seoul: National Evidence-based Healthcare Collaborating Agency (NECA); 2014:14.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84. CrossRefPubMed
Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 21 Mar 2017.
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. In: Deeks JJ, Higgins JP and Altman DG, editors. Heterogeneity. Chichester: Wiley; 2008. p. 276–81.
Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1).
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Statistical Methodology). 2002;64:583–639. CrossRef
Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Lakhal SB. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6:1. CrossRef
Durante-Mangoni E, Signoriello G, Andini R, Mattei A, Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349–58. CrossRefPubMed
Amin M, Rashad A, Fouad A, Azeem AA. Re-emerging of colistin for treatment of nosocomial pneumonia due to Gram negative multi-drug resistant pathogens in critically ill patients. Egypt J Chest Dis Tuberc. 2013;62:447–51. CrossRef
Frantzeskaki F, Karampi ES, Papadopoulos P, Paramythiotou E, Theodorakopoulou M, Flevari A, Rizos M, Diakaki C, Armaganidis A, Dimopoulos G. Comparative study of the combination of high doses of ampicilline/sulbactam with colistin versus meropenem with colistin in ventilatior associated pneumonia caused by Acinetobacter baumannii. Intensive Care Med. 2013;39(Suppl 2):S383.
Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102. CrossRefPubMedPubMedCentral
Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob. 2016;15:1. CrossRef
Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, Espejo-Gutierrez DTE, Artero-Gonzalez ML, Corcia-Palomo Y, Bautista-Paloma J. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59:31. CrossRef
Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010;16:1230–6. CrossRefPubMed
Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya AC, De Pascale G, Grilli E, Tumbarello M, Akova M. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58:851–8. CrossRefPubMedPubMedCentral
Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. CHEST J. 2013;144:1768–75. CrossRef
Zalts R, Neuberger A, Hussein K, Raz-Pasteur A, Geffen Y, Mashiach T, Finkelstein R. Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin–sulbactam. Am J Ther. 2016;23:e78–85. CrossRefPubMed
Lin HS, Lee MH, Cheng CW, Hsu PC, Leu HS, Huang CT, Ye JJ. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47(6):370–8. CrossRef
Busey K, Ferreira J, Aldridge P, Johnson D, Guzman N, Jankowski CA. Treatment efficacy of ampicillin/sulbactam in comparison to alternative beta-lactams for severe Acinetobacter baumannii infections. Infect Dis. 2016;48:775–7. CrossRef
Hoosen A, Baba K. In-vitro activity of fosfomycin against clinical isolates of carbapenem resistant Acinetobacter baumannii complex and Pseudomonas aeruginosa at a South African academic hospital. Int J Infect Dis. 2016;45(Suppl 1):92.
Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–9. CrossRefPubMed
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111. CrossRefPubMedPubMedCentral
Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, Janos G, Garot D, et al. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial. Chest. 2017;151:1239–46. CrossRefPubMed
Michalopoulos AS, Falagas ME. Inhaled antibiotics in mechanically ventilated patients. Minerva Anestesiol. 2014;80:236–44. PubMed
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:1847–54. CrossRefPubMedPubMedCentral
- Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis
Su Young Jung
Seung Hee Lee
Soo Young Lee
Eun Kyoung Chung
Jangik I. Lee
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II